Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup
Carien L Creutzberg,Jae-Weon Kim,Gemma Eminowicz,Emma Allanson,Lauriane Eberst,Se Ik Kim,Remi A Nout,Jeong-Yeol Park,Domenica Lorusso,Linda Mileshkin,Petronella B Ottevanger,Alison Brand,Delia Mezzanzanica,Amit Oza,Val Gebski,Bhavana Pothuri,Tania Batley,Carol Gordon,Tina Mitra,Helen White,Brooke Howitt,Xavier Matias-Guiu,Isabelle Ray-Coquard,David Gaffney,William Small Jr,Austin Miller,Nicole Concin,Matthew A Powell,Gavin Stuart,Michael A Bookman,participants of the 2023 Gynecologic Cancer InterGroup Endometrial Cancer Consensus Conference on Clinical Research,Pilar Barretina-Ginesta,Katherine Bennett,Jonathan Berek,Regina Berger,Line Bjørge,Ingrid Boere,Donal Brennan,Ilan Bruchim,Ting-Chang Chang,Adriana Chavez Blanco,Xiaojun Chen,Nicoletta Colombo,Emma Crosbie,Hannelore Denys,Linda Duska,Filip Fruehauf,Eva Maria Gomez Garcia,Toon van Gorp,Christoph Grimm,Gustavo Guitmann,Kathy Han,Lars Hanker,Kenichi Harano,Kosei Hasegawa,C Simon Herrington,Philip Ip,Florence Joly,Pearly Khaw,Elise Kohn,Rebecca Kristeleit,Judith Kroep,Alexandra Leary,Jung-Yun Lee,Stephanie Lheureux,Jihong Liu,Helen Mackay,Sven Mahner,Andrea Mariani,Jessica McAlpine,Yoshiki Mikami,Mansoor Raza Mirza,Asima Mukhopadhyay,Shoji Nagao,Joseph Ng,Angelica Nogueira-Rodrigues,Zoltán Novák,Jennifer O'Donnell,Sherill Osborne,J Alejandro Perez-Fidalgo,Margarita Romeo Marin,Rahul Roy Chowdhury,Azmat Sadozye,Tamar Safra,Claire Scott,Jalid Sehouli,Brian Slomovitz,David Tan,Alexandra Taylor,Giorgio Valabrega,Ana Veneziani,Karen Verhoeven,Marcus Vetter,Julian Wampfler,Shannon Westin,Pauline Wimberger,Paolo Zola
DOI: https://doi.org/10.1016/S1470-2045(24)00192-X
Abstract:The Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Consensus Conference on Clinical Research (ECCC) was held in Incheon, South Korea, Nov 2-3, 2023. The aims were to develop consensus statements for future trials in endometrial cancer to achieve harmonisation on design elements, select important questions, and identify unmet needs. All 33 GCIG member groups participated in the development, refinement, and finalisation of 18 statements within four topic groups, addressing adjuvant treatment in high-risk disease; treatment for metastatic and recurrent disease; trial designs for rare endometrial cancer subgroups and special circumstances; and specific methodology and adaptation for trials in low-resource settings. In addition, eight areas of unmet need were identified. This was the first GCIG Consensus Conference to include patient advocates and an expert on inclusion, diversity, equity, and access to take part in all aspects of the process and output. Four early-career investigators were also selected for participation, ensuring that they represented different GCIG member groups and regions. Unanimous consensus was obtained for 16 of the 18 statements, with 97% concordance for the remaining two. Using the described methodology from previous Ovarian Cancer Consensus Conferences, this conference did not require even one minority statement. The high acceptance rate following active involvement in the preparation, discussion, and refinement of the statements by all representatives confirmed the consensus progress within a global academic setting, and the expectation that the ECCC will lead to greater harmonisation, actualisation, inclusion, and resolution of unmet needs in clinical research for individuals living with and beyond endometrial cancer worldwide.